MedAdvisor Limited’s
(ASX:MDR) service agreement with global pharmaceuticals giant, GlaxoSmithKline Australia Pty Ltd, has been extended by another 12 months.
MedAdvisor is an electronic medication management software. It connects patients to their local pharmacy and provides them with real time access to their personal medication records.
Under the agreement, GSK will continue to provide tailored messages to patients that have been prescribed medications within its respiratory portfolio.
MedAdvisor says it will receive Patient Engagement Program revenue from GSK for the use of its software.
MedAdvisor reported a net loss of $1.1 million at 31 December 2015.
